Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Concert Pharma (CNCE) Reports Q2 EPS of $0.16
August 5, 2021 7:55 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q2 EPS of $0.16, versus ($0.41) reported last year. Revenue for the quarter came in at $32 million, versus $6.4 million reported last year.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More